Reversible derivatization to enhance enzymatic synthesis: Chemoenzymatic synthesis of doxorubicin-14-fl-esters

Biotechnology and Bioengineering

Volumn 101, Issue 3, 2008, Pages 435-440

  Cotterill, Ian C ^a   Rich, Joseph O ^b   Scholten, Marc D ^a   Mozhaeva, Lyudmila ^a   Michels, Peter C ^a  

^a ALBANY MOLECULAR RESEARCH INC   (United States)

^b NATIONAL CENTER FOR AGRICULTURAL UTILIZATION RESEARCH   (United States)

Author keywords

Doxorubicin esterification; Enzymatic synthesis; Reversible derivatization

Indexed keywords

ACYL DONORS; CHEMO-ENZYMATIC SYNTHESIS; CHROMATOGRAPHIC PURIFICATION; DERIVATIZATION; DOXORUBICIN; DOXORUBICIN ESTERIFICATION; DOXORUBICIN HYDROCHLORIDE; ENZYMATIC SYNTHESES; ENZYMATIC SYNTHESIS; REGIO-SELECTIVE; REVERSIBLE DERIVATIZATION; SCALE-UP;

CHEMICAL REACTIONS; ESTERIFICATION; ESTERS;

ORGANIC COMPOUNDS;

DOXORUBICIN; DOXORUBICIN 14 O ESTER; DOXORUBICIN 14 O HEPTANOATE; DOXORUBICIN 14 O HEXANOATE; TRIACYLGLYCEROL LIPASE; UNCLASSIFIED DRUG;

ARTICLE; CATALYSIS; CATALYST; CHEMOENZYMATIC SYNTHESIS; DERIVATIZATION; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME SUBSTRATE COMPLEX; ESTERIFICATION; HUMAN; HUMAN CELL; REACTION ANALYSIS; TRANSESTERIFICATION;

ACYLATION; ANTIBIOTICS, ANTINEOPLASTIC; DOXORUBICIN; ESTERIFICATION; LIPASE; MOLECULAR STRUCTURE; STEREOISOMERISM;

EID: 53549093868     PISSN: 00063592     EISSN: 10970290     Source Type: Journal    
DOI: 10.1002/bit.21929     Document Type: Article

References (31)

1. Altreuter DH, Clark DS, Michels PC, Rich JO, Meckler H, Dordick JS. 2003. Methods for preparing doxorubicin derivatives. PCT WO 03/057687.
2. Arcamone F, Cassineili G, Fantini G, Grein A, Orezzi P, Pol C, Spalla C. 1969. Adriamycin, 14-hydroxydaimomycin, a new antitumor antibiotic from S. Peucetius var. caesius. Biotechnol Bioeng 11:1101-1110.
3. Arcamone F, Franceschi G, Minghetti A, Penco S, Redaelli S. 1974. Synthesis and biological evaluation of some 14-O-acyl derivatives of adriamycin. J Med Chem 17:335-337.
4. Blum RH, Carter SK. 1974. A new anticancer drug with significant clinical activity. Ann Intern Med 80:249-259.
5. Bouma J, Beijnen JH, Bult A, Underberg WJM. 1986. Anthracycline antitumour agents. A review of physicochemical, analytical and stability properties. Pharm Weekbl [Sci] 8:109-133.
6. Bridon DP, Leger R, Huang X, Milner PG, Smith D, Ezrin AM. 2001. Methods and compositions for producing long lasting antineoplastic agents. PCT WO 01/ 17614.
7. Buckley MM, Lamb HM. 1997. Oral idarubicin. A. review of its pharmacological properties and clinical efficacy in the treatment of haemato-logical malignancies and advanced breast cancer. Drugs Aging 11:61-86.
8. Corey EJ, Suggs JW. 1973. Selective cleavage of allyl ethers under mild conditions by transition metal reagents. J Org Chem 38:3223-3224.
9. Cotterill IC, Rich JO. 2005. Chemoenzymatic synthesis of N-trifluoroacetyl doxorubicin-14-valerate (valrubicin). Org Proc Res Dev 9:818-821.
10. Dantchev D, Balercia G, Bourut C, Anjo A, Maral R, Mathe G. 1984. Comparative microscopic study of cardiotoxicity and skin toxicity of anthracycline analogs. Biomed Pharm 38:322-328.
11. Degn P, Zimmermann W. 2001. Optimization of carbohydrate fatty acid ester synthesis in organic media by a lipase from Candida antarctica. Biotechnol Bioeng 74:483-491.
12. Ema T, Kageyama M, Koranaga T, Sakai T. 2003. Highly enantioselective lipase-catalyzed reactions at high temperatures up to 120 C in organic solvent. Tet Asymm 14:3943-3947.
13. Ghione M. 1978. Cardiotoxic effects of antitumor agents. Cancer Chemother Pharmacol 1:25-34.
14. Ghirmai S, Mume E, Tomachev V, Sjöberg S. 2005. Synthesis and radio-iodination of some daunorubicin and doxorubicin derivatives. Carbohydrate Res 340:15-24.
15. Hortobagyi GN. 1997. Anthracyclines in the treatment of cancer. An overview. Drugs 54:1-7.
16. Israel M, Potti G. 1982. Adriamycin analogs. Preparation and biological evaluation of some N-perfluoroacyl analogs of daunorubicin, adriamycin, and N-(trifluoroacetyl)adriamycin 14-valerate and their 9,10-anhydro derivatives. J Med Chem 25:187-191.
17. Kunz H, Unverzagt C. 1984. The allyloxycarbonyl (Aloc) moiety - Conversion of an unsuitable into a valuable amino protecting group for peptide synthesis. Angew Chem Int Ed Engl 23:436-437.
18. Kuznetsov DD, Alsikafi NF, O'Conner RC, Steinberg GD. 2001. Intravesical valrubicin in the treatment of carcinoma in situ of the bladder. Expert Opin Pharmacotherapy 2:1009-1013.
19. Mead Johnson Oncology Products, 2001. Rubex® (doxorubicin hydrochloride for injection) product information sheet (March 2001 revision).
20. Michels PC, Rich JO, Meckler H, Cotterill I. 2003. Methods for preparing anthracyclinone derivatives and anthracyclinone derivatives per se. PCT WO 03/057896.
21. Nagy A, Schally AV, Armatis P, Szepeshazi K, Halmos G, Kovacs M, Zarandi M, Groot K, Miyazaki M, Jungwirth A, Horvath J. 1996. Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative500-1000 times more potent. Proc Nat Acad Sci 93:7269-7273.
22. Newling DW, Hetherington J, Sundaram SK, Robinson MRG, Kisbenedek L. 2001. The use of valrubicin for the chemoresection of superficial bladder cancer - A marker lesion study. Eur Urol 39:643-647.
23. Onrust SV, Lamb HM. 1999. Valrubicin. Drugs Aging 15:69-75.
24. Rho YS, Park S, Kim W-J, Kim G, Yoo DJ, Kang H-S, Chung SR. 2002. Synthesis of new anthracycline derivatives containing pyruvic, aspartic, or N-acetylaspartic acid molecule. Synth Commun 32: 1961-1975.
25. Rich JO, Michels PC, Khmelnitsky YL. 2002. Combinatorial biocatalysis. Curr Opin Chem Biol 6:161-167.
26. Roh IK, Rha SY, Lee CI, Lee KH, Lee JJ. 1998. Phase I clinical trial: Pharmacokinetics of a novel anthracycline, DA-125 and metabolites. Single dose study. Int J Clin Pharmacol Therapeut 36:312-319.
27. Soumanou MM, Bornscheuer UT, Schmid RD. 1998. Two-step enzymatic reaction for the synthesis of pure structured triacylglycerides. J Am Oil Chem Soc 75:703-710.
28. Strauss DG. 1978. Anthracyclines - Modern tumour inhibiting agents. Folia Microbiol 23:152-161.
29. Weiss RB. 1992. The anthracyclines: Will we ever find a better doxorubicin? Semin Oncol 19:670-686.
30. Young RC, Ozols RF, Myers CE. 1981. The anthracycline antineoplastic drugs. N Engl J Med 305:139-153.
31. Zaks A, Klibanov AM. 1984. Enzymatic catalysis in organic media at 100 degrees C. Science 224:1249-1251.